Summary of IN8bio Conference Call - February 05, 2026 Company Overview - **Company**: IN8bio (NasdaqGM:INAB) - **Focus**: Development of cellular therapies using gamma delta T cells - **Key Personnel**: William Ho (CEO), Dr. Larry Lamb (Chief Scientific Officer) [1][2] Core Programs and Pipeline - **Ongoing Programs**: - **INB-100**: Allogeneic cell therapy for leukemia patients undergoing transplantation, currently enrolling an expansion cohort with updated phase one data expected by year-end [3] - **INB-619**: T cell engager platform targeting CD19 for both oncology and autoimmune diseases [3] - **INB-200 and INB-400**: Genetically modified gamma-delta T cell programs targeting solid tumors, particularly glioblastoma [3][4] Glioblastoma Treatment Insights - **Mechanism of Action**: Targets the DNA damage response (DDR) pathway, which is fundamental to all cells, making it potentially applicable to various solid tumors [33] - **Clinical Trial Results**: - Patients treated with INB-200 and INB-400 showed a median progression-free survival (PFS) of 13 months, compared to 6.6 months in the control group [14] - Overall survival (OS) for treated patients reached 17.2 months, with some patients remaining progression-free for over 4 years [15][47] - No major toxicity signals or adverse events reported [11] T Cell Engager Platform - **INB-619**: A unique CD19 targeting T cell engager designed to minimize cytokine release syndrome (CRS) while effectively depleting B cells [22][27] - **Comparative Efficacy**: INB-619 demonstrated comparable or superior potency to existing B-cell depleters like Amgen's blinatumomab and Roche's mosunitumab, with a significantly wider therapeutic window [26][27] Financial and Operational Updates - **Recent Financing**: Raised $20.1 million led by Coastlands Capital, with participation from Franklin Templeton and other investors, providing runway through 2027 [28][50] - **Upcoming Milestones**: - Public peer-reviewed publication of glioblastoma data - FDA guidance on regulatory path for glioblastoma program - Mouse data for INB-619 expected by late summer [53] Additional Insights - **Market Positioning**: IN8bio has chosen not to pursue autoimmune diseases with cell therapies, focusing instead on oncology due to concerns about the safety and efficacy of existing treatments in that area [20] - **Histopathology Findings**: Analysis of treated patients showed significant infiltration of gamma-delta T cells, indicating effective targeting of tumors [19] Conclusion - IN8bio is making significant strides in the development of innovative therapies for glioblastoma and leukemia, with promising clinical results and a solid financial foundation to support ongoing research and development efforts [29]

当前，中国资产再度成为全球资本关注的焦点。 近日，景顺、富达国际、摩根士丹利基金等多家外资机构密集发布最新投资展望报告，不约而同地对中 国资产投下"信任票"，并认为在中国经济稳健复苏、股票市场估值吸引力突出以及科技创新动能持续增 强的背景下，中国资产展现出显著的长期配置价值。 经济增长保持韧性 多家外资机构对2026年中国经济增长持乐观态度，一致认为在政策有力支持下，中国经济将延续稳定向 好态势。 景顺亚太区全球市场策略师赵耀庭认为，2025年中国国内生产总值(GDP)同比增长5.0%，与预期目标相 符，经济增长主要得益于具有韧性的制造业和强劲的出口。展望2026年，预计中国经济将保持稳定增 长，动力来自人工智能相关投资加速，以及一系列旨在促进投资和提振内需消费的支持性政策的推动。 在富达国际亚洲经济学家刘培乾看来，中国宏观经济前景"日趋平衡且更具韧性"，主要得益于制造业动 能、多元化出口市场，以及颇具韧性的基础设施投资。 景顺中国内地及香港首席投资总监马磊表示，对2026年中国股票市场继续保持乐观，持续改善的基本面 及长期增长动力有望推动市场进入更可持续的结构性增长周期。其一，企业盈利已释放出明确的复苏信 ...

Financial Data and Key Metrics Changes - QIAGEN exceeded its fourth quarter 2025 Outlook with net sales of $540 million, growing 1% at constant exchange rates (CER) compared to flat sales development expected against Q4 2024 [5][12] - Adjusted diluted EPS for Q4 was $0.62 at CER, surpassing the Outlook of approximately $0.60 [5][12] - For the full year 2025, net sales reached $2.09 billion, up 5% at CER, at the upper end of the Outlook of 4%-5% growth [5][12] - Adjusted diluted EPS for the full year increased to $2.40 at CER, exceeding the initial Outlook by $0.12 [5][12] Business Line Data and Key Metrics Changes - Sample Technologies achieved 5% growth at CER in Q4 and 2% for the full year, driven by demand for automated consumables [6][13] - QuantiFERON sales grew 5% at CER in Q4 and 10% for the full year, supported by ongoing conversion in the latent TB testing market [7][14] - QIAstat-Dx grew 15% at CER in Q4 and 24% for the full year, aided by menu expansion and a growing install base [7][14] - QIAcuity saw double-digit growth in consumables, with over 3,200 instruments installed globally [7][14] - The bioinformatics business, QIAGEN Digital Insights, continued to grow, bolstered by demand from both research and clinical customers [8][24] Market Data and Key Metrics Changes - Sales in the Europe, Middle East, and Africa region increased by 5% at CER in Q4, with Belgium, the Netherlands, Spain, and the UK as top performers [16] - In the Americas, sales declined by 1% at CER, with the U.S. market remaining flat, partly due to the government shutdown [16] - Asia-Pacific-Japan region sales were flat, with a low-teens decline in China, which represents only about 4% of total sales [16][56] Company Strategy and Development Direction - QIAGEN aims for at least $2 billion in combined sales from its growth pillars by 2028, reflecting continued demand and long-term investment strategies [6][34] - The company is focused on disciplined execution, cost management, and investment in growth pillars, including the recent acquisition of Parse Biosciences to enhance Sample Technologies [9][19] - New product launches are expected to contribute significantly to growth, with QIAsymphony Connect and QIAmini targeting automation across various applications [20][68] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a cautious funding and capital spending environment but expressed confidence in achieving growth targets due to a strong pipeline of new product launches [32][66] - The company anticipates gradual improvement in the funding environment throughout 2026, with expectations for mid-single-digit growth in the total market [66] - QIAGEN's 2026 Outlook includes sales growth of at least 5% at CER and adjusted EPS of at least $2.50 at CER [26][31] Other Important Information - QIAGEN returned over $1.1 billion to shareholders since 2024 and plans to continue this trend alongside selective acquisitions [9][18] - The company is reviewing its adjusted operating income margin target of at least 31% for 2028, with expectations for continued margin improvement despite headwinds from tariffs and currency movements [17][31] Q&A Session Summary Question: Insights on new product launches and growth targets - Management highlighted that new product launches are expected to open new markets and contribute to growth, with confidence in achieving the $250 million target for digital PCR by 2028 despite previous delays [37][39] Question: Comments on potential acquisition rumors - Management stated that while the market is undergoing consolidation, QIAGEN remains focused on its growth plan and does not comment on rumors [45] Question: Update on CEO succession search - The search for a new CEO is ongoing, with both internal and external candidates being considered, and updates will be provided as progress is made [46] Question: Margin expansion and operating leverage - Management expects significant margin improvement in 2026, driven by gross margin improvements and operational efficiency programs, despite headwinds from acquisitions and tariffs [49][50] Question: Growth outlook in China - Management confirmed limited exposure to China, with expectations for low single-digit to negative growth due to market conditions and political factors [56][57] Question: QIAstat-Dx placements and respiratory season outlook - Management expressed confidence in achieving growth targets for QIAstat-Dx, with expectations for continued relevance in respiratory testing [71][72]

2月5日上午10时，国务院新闻办公室举行新闻发布会。国家市场监督管理总局标准技术管理司司长刘洪 生介绍了中国标准"走出去"的情况。 他表示，2025年，市场监管总局以标准互联互通服务高水平对外开放，主要成效体现在三个方面： 一是打通双向通道，推动标准"引进来"和"走出去"协同并进。在"引进来"方面，我们修订发布《采用国 际标准管理办法》，突出"精准采用""高效转化"，加快将国际标准转化为国内标准。截至2025年底，我 国总体国际标准转化率已达88.9%，2025年全年转化1510项国际标准，其中文化、气象等领域的转化率 达到100%，航空、建材、机械等领域的转化率超过90%。在"走出去"方面，2025年在新能源、传统医 学、脑机接口等领域，牵头制定发布ISO、IEC国际标准285项，同比增长26.7%。在生物技术、人工智 能、工业网络等领域，向ISO、IEC提出国际标准提案505项，同比增长15.8%。 下一步，市场监管总局将结合海南自由贸易港和自贸区建设等需求，推动开展标准制度型开放试点，邀 请国际专家参与我国标准体系的建设，加大重点领域标准外文版供给，培养更多"懂标准、通国际"的复 合型人才，支撑高质量共 ...

Core Viewpoint - The biotechnology industry is at a crossroads, with a paradox of rising internal confidence despite external uncertainties, leading to a historical shift in treatment areas and global innovation landscape [2]. Group 1: Financing Environment - The financing environment for the biotechnology industry has shifted from enthusiasm to a rational panic, with 92% of investors expressing confidence in achieving the next investment milestone, despite a significant increase in companies seeking additional R&D funding from 14% in 2023 to 41% in 2025 [3]. - The capital allocation logic is fundamentally changing, with venture capital moving from a "broad net" strategy to "mega bets," resulting in a stark resource polarization where leading companies receive ample funding while many small and medium-sized biotech firms face liquidity crises [3][4]. Group 2: Treatment Landscape Changes - Neuroscience has emerged as the leading research focus in biotechnology, surpassing oncology for the first time, with an active rate of 44% compared to oncology's 30%, indicating a systemic shift in industry risks and technological breakthroughs [5]. - The marginal returns on oncology drug development are decreasing due to intense competition in popular targets, while breakthroughs in neuroscience related to diseases like Alzheimer's are reigniting industry ambitions [5]. Group 3: Technological Modalities - Cell therapy has become the most active technological modality at 40%, while small molecule drugs account for 28%, indicating a shift towards more complex biotechnological innovations [6]. Group 4: China's Role in Biotechnology - China is solidifying its position as a "biotechnology superpower," ranking in the top ten of the global innovation index and matching the U.S. in clinical trial numbers, presenting significant opportunities for venture capital and multinational pharmaceutical companies [7][8]. - However, the rise of China's biotechnology sector is viewed as a strategic challenge by Western governments, leading to increased regulatory scrutiny and geopolitical tensions [8]. Group 5: Talent and AI in Drug Development - The complexity of drug development and talent acquisition remains a significant concern, with talent demand in the Asia-Pacific region being three times higher than in Europe and the U.S. due to rapid industry growth [9]. - The biotechnology industry is increasingly turning to artificial intelligence (AI) and digital tools to enhance R&D efficiency, with 76% of stakeholders expecting AI to accelerate their development processes in the next two years [10].

Core Insights - The Cuban government has announced an annual investment plan totaling 1.74 trillion pesos to address urgent economic and social development needs [1] Group 1: Investment Allocation - 67% of the funds will be focused on three priority areas: food production, industrial revitalization, and the reconstruction of the electricity system [1] - 95% of the investment will be directed towards ongoing projects aimed at enhancing the self-sufficiency of strategic industries [1] Group 2: Strategic Projects - The plan includes modernization of the Antillana steel plant in collaboration with Russia, expansion of cement production capacity, and various agricultural, forestry, tobacco, and livestock projects [1] - New photovoltaic power plants and maintenance of thermal power plants are also part of the investment strategy [1] Group 3: Infrastructure and Social Welfare - The investment will cover housing, water management, tourism, and other infrastructure and social welfare areas, with plans to construct over 9,000 state-owned housing units and renovate 38 tourism hotels [1] - Upgrades to the national water supply system and support for the production of essential medicines and biotechnology research are also included [1]

Core Insights - Bio-Techne exceeded analysts' expectations for second-quarter revenue and profit, driven by strong demand for its products utilized in drug development [1] Company Performance - The company reported better-than-expected financial results for the second quarter, indicating robust operational performance [1] Market Demand - There is a significant demand for Bio-Techne's products in the drug development sector, which has positively impacted its financial outcomes [1]

Core Viewpoint - The "Changping Model" selection activity for 2025 has recognized exemplary individuals who contribute to the spirit of the times and promote the development of Changping District through their dedication and actions [1]. Group 1: Recognition of Exemplary Individuals - The event has highlighted a diverse group of individuals from various sectors, showcasing their impactful stories and contributions to society [1]. - The selected individuals include Zhao Tianmeng, Xu Peng, Zhang Nan, and others, who have demonstrated commitment and innovation in their respective fields [1]. Group 2: Contributions in Science and Technology - Zhao Tianmeng, CTO of Beijing Qihe Biotechnology Co., has made significant advancements in gene editing, developing a new base editing system recognized as a milestone in the field [5][6]. - His work has led to the creation of the "PrimeRoot" technology, which drastically reduces the time for gene insertion in rice from years to weeks, earning accolades in scientific publications [6]. Group 3: Community and Emergency Services - Xu Peng, a firefighter, has excelled in both administrative and operational roles, improving documentation processes and training programs within the fire department [10][11]. - Zhang Nan, a police officer, has implemented innovative risk management mechanisms, effectively resolving numerous community disputes and enhancing public safety [15][16]. Group 4: Cultural Preservation and Education - Gao Xuhong, a villager, has dedicated her life to preserving traditional cultural practices, creating educational materials, and training new generations in the art of Huabao drum [20][21]. - Her initiatives have fostered community engagement and cultural continuity, impacting nearly a thousand students across various educational institutions [21]. Group 5: Healthcare and Medical Innovation - He Baowei, a physician, has significantly improved healthcare access in Xinjiang through his medical expertise and community outreach, increasing patient visits and establishing a robust healthcare framework [30][31]. - His efforts have led to the establishment of a medical work studio, enhancing the local healthcare system and benefiting thousands of residents [31]. Group 6: Environmental and Renewable Energy Initiatives - Jiang Hechuan, a senior engineer at China Huaneng Group, has developed a flexible photovoltaic support system that optimizes land use and reduces material costs in solar energy projects [25][26]. - His contributions have been recognized as pivotal in advancing the renewable energy sector, with numerous patents and published research [26]. Group 7: Social Responsibility and Community Service - Lan Dong, a business owner, has integrated social responsibility into his operations by providing free haircuts to the elderly and underprivileged, demonstrating a commitment to community welfare [51][52]. - His initiatives have served over 80,000 elderly individuals, showcasing the impact of local businesses in addressing social needs [52]. Group 8: Future Directions - The Changping District aims to continue promoting the "Changping Model" initiative, fostering a culture of learning from exemplary figures and encouraging civic engagement for high-quality development [54].

格隆汇2月4日丨海利生物(603718.SH)公布，公司于近日收到全资子公司上海捷门生物技术有限公司控 股子公司成都鸬鹚生物技术有限公司（以下简称"鸬鹚生物"）通知，鸬鹚生物已顺利通过高新技术企业 认定，并取得由四川省科学技术厅、四川省经济和信息化厅、四川省财政厅、国家税务总局四川省税务 局联合颁发的《高新技术企业证书》，证书编号：GR202551001452，发证日期：2025年12月2日，本次 系鸬鹚生物首次获得高新技术企业认定。 ...

Group 1 - The core point of the article is that Saintgen Biotech has entered into a global research and licensing agreement with Genentech to develop an RNA interference (RNAi) therapy [1] - Under the agreement, Saintgen Biotech will grant Genentech exclusive global rights for the development and commercialization of the RNAi drug, while Saintgen will handle early-stage research [1] - Genentech will be responsible for all subsequent clinical development and commercialization activities of the drug [1] Group 2 - Saintgen Biotech's proprietary RNAi drug development platform includes novel drug chemical modifications and delivery technologies, which can be utilized to develop potential breakthrough siRNA drugs across multiple disease areas [1] - According to the agreement terms, Saintgen Biotech will receive an upfront payment of $200 million, with the potential to earn up to $1.5 billion in development and sales milestone payments, along with tiered royalties [1]